Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 11/2012

01-11-2012 | Letter to the Editor

Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

Authors: Adriano Salaroli, Giuseppina Loglisci, Alessandra Serrao, Giuliana Alimena, Massimo Breccia

Published in: Annals of Hematology | Issue 11/2012

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Mokhtari D, Welsh N (2009) Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 118:241–247CrossRef
2.
Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ (2011) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice. J Oncol Pharm Pract 17:197–202PubMedCrossRef
3.
Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G (2004) Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 22:4653–4655PubMedCrossRef
4.
Breccia M, Alimena G (2009) The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism. Leuk Res 33:871–875PubMedCrossRef
5.
Guiteau J, Fanucchi M, Folpe A, Staley CA 3rd, Kooby DA (2006) Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. Am Surg 72:1225–1230PubMed
6.
Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweji J, Sleijfer S (2006) Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 24:e30–e31PubMedCrossRef
7.
Hägerkvist R, Sandler S, Mokhtari D, Welsh N (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic pre-conditioning. FASEB J 21:618–628PubMedCrossRef
8.
Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC (2010) Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95:3763–3767PubMedCrossRef
9.
Dingli D, Wolf RC, Vella A (2007) Imatinib and type 2 diabetes. Endocr Pract 13:126–130PubMed
10.
Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in non-obese diabetic mice. Proc Natl Acad Sci U S A 105:18895–18900PubMedCrossRef
Metadata
Title
Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes
Authors
Adriano Salaroli
Giuseppina Loglisci
Alessandra Serrao
Giuliana Alimena
Massimo Breccia
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 11/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1493-3

Other articles of this Issue 11/2012

Annals of Hematology 11/2012 Go to the issue

Letter to the Editor

A novel frameshift mutation Gly239Serfs*8 in the PROC gene results in protein C deficiency in a Korean patient

Original Article

Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice

Original Article

Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study

Letter to the Editor

Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspects

Original Article

Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting

Original Article

The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits